Proteomic tool vendors may not see much benefit from the $10.4 billion stimulus package passed by the US government in February, according to a report from an investment firm.

Last week, Thomas Weisel Partners issued a report on a survey of 54 life-science researchers that sought to gauge the current funding environment, expectations for future funding, and likely beneficiaries.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.